Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Clear Secure Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B), while Clear Secure Inc trades at $43.36 (market cap $4.39B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 29.2× Clear Secure Inc's market cap, and Clear Secure Inc pays a 1.35% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Clear Secure Inc for 19 Days on average.
| VRTX | YOU | |
|---|---|---|
Market Cap | $128.16B | $4.39B |
Volume | 806,603 | 1,899,845 |
Sector | Health | Technology |
52-Week High | $557.96 | $62.36 |
52-Week Low | $407.37 | $29.61 |
Typical Hold Time | 120 Days | 19 Days |
Enterprise Value | $122.29B | $3.54B |
Dividend Yield | — | 1.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Clear Secure (YOU) trades at $42.58, up 2.6% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 27% revenue growth in Q2 2026, beating earnings estimates, and robust profitability margins. Recent partnership with CrowdStrike and corporate membership launch highlight growth initiatives. Analyst consensus is mixed with a $61.40 price target representing 44% upside potential.
The stock presents growth potential driven by expanding membership base and enterprise partnerships, but faces risks from competitive pressures and potential execution challenges. Current valuation at 28.77 P/E appears reasonable given growth trajectory, though technical indicators show some overbought conditions that may limit near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
